EA201590883A1 - Лечение помалидомидом рака у субъекта с почечной недостаточностью - Google Patents
Лечение помалидомидом рака у субъекта с почечной недостаточностьюInfo
- Publication number
- EA201590883A1 EA201590883A1 EA201590883A EA201590883A EA201590883A1 EA 201590883 A1 EA201590883 A1 EA 201590883A1 EA 201590883 A EA201590883 A EA 201590883A EA 201590883 A EA201590883 A EA 201590883A EA 201590883 A1 EA201590883 A1 EA 201590883A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- subject
- cancer
- pomalidomide
- renal failure
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 208000001647 Renal Insufficiency Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 201000006370 kidney failure Diseases 0.000 title abstract 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000688 pomalidomide Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722722P | 2012-11-05 | 2012-11-05 | |
| US201361764466P | 2013-02-13 | 2013-02-13 | |
| PCT/US2013/068237 WO2014071280A1 (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201590883A1 true EA201590883A1 (ru) | 2015-09-30 |
Family
ID=50628132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590883A EA201590883A1 (ru) | 2012-11-05 | 2013-11-04 | Лечение помалидомидом рака у субъекта с почечной недостаточностью |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150297579A1 (enExample) |
| EP (1) | EP2914112A4 (enExample) |
| JP (1) | JP2015535291A (enExample) |
| CN (1) | CN104902754A (enExample) |
| AU (1) | AU2013337352A1 (enExample) |
| BR (1) | BR112015010039A2 (enExample) |
| CA (1) | CA2889987A1 (enExample) |
| EA (1) | EA201590883A1 (enExample) |
| HK (1) | HK1214552A1 (enExample) |
| IL (1) | IL238563A0 (enExample) |
| MX (1) | MX2015005548A (enExample) |
| NI (1) | NI201500063A (enExample) |
| PH (1) | PH12015501002A1 (enExample) |
| SG (1) | SG11201503456TA (enExample) |
| WO (1) | WO2014071280A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591902A1 (ru) * | 2013-04-02 | 2016-02-29 | Селджин Корпорейшн | Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы |
| CA3025145A1 (en) * | 2015-05-22 | 2016-12-01 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
| CN105456232A (zh) * | 2015-09-08 | 2016-04-06 | 刘剑 | 一种泊马度胺速溶膜剂及其制备方法 |
| CN109071460B (zh) * | 2016-03-02 | 2022-08-09 | 转化药物开发有限责任公司 | 氨基苯并咪唑衍生物 |
| WO2018013689A1 (en) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| CN108721304B (zh) * | 2017-04-17 | 2020-10-16 | 北京大学 | 用于治疗肿瘤的药物组合物及其用途 |
| AU2018328308A1 (en) * | 2017-09-06 | 2020-04-16 | Translational Drug Development, Llc | Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| GB202012160D0 (en) * | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
| EP4479082A2 (en) * | 2022-02-15 | 2024-12-25 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP5339588B2 (ja) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬 |
| JP5553275B2 (ja) * | 2010-03-31 | 2014-07-16 | 国立大学法人金沢大学 | 金属錯体およびこれを有効成分として含有する抗がん剤 |
| MX2013012083A (es) * | 2011-04-18 | 2014-04-16 | Celgene Corp | Biomarcadores para el tratamiento de mieloma multiple. |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
-
2013
- 2013-11-04 HK HK16102558.2A patent/HK1214552A1/zh unknown
- 2013-11-04 EP EP13850977.3A patent/EP2914112A4/en not_active Withdrawn
- 2013-11-04 WO PCT/US2013/068237 patent/WO2014071280A1/en not_active Ceased
- 2013-11-04 EA EA201590883A patent/EA201590883A1/ru unknown
- 2013-11-04 MX MX2015005548A patent/MX2015005548A/es unknown
- 2013-11-04 BR BR112015010039A patent/BR112015010039A2/pt not_active IP Right Cessation
- 2013-11-04 CN CN201380069405.4A patent/CN104902754A/zh active Pending
- 2013-11-04 AU AU2013337352A patent/AU2013337352A1/en not_active Abandoned
- 2013-11-04 SG SG11201503456TA patent/SG11201503456TA/en unknown
- 2013-11-04 US US14/440,333 patent/US20150297579A1/en not_active Abandoned
- 2013-11-04 CA CA2889987A patent/CA2889987A1/en not_active Abandoned
- 2013-11-04 JP JP2015540844A patent/JP2015535291A/ja active Pending
-
2015
- 2015-04-30 IL IL238563A patent/IL238563A0/en unknown
- 2015-05-04 NI NI201500063A patent/NI201500063A/es unknown
- 2015-05-05 PH PH12015501002A patent/PH12015501002A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2889987A1 (en) | 2014-05-08 |
| SG11201503456TA (en) | 2015-05-28 |
| BR112015010039A2 (pt) | 2017-07-11 |
| WO2014071280A1 (en) | 2014-05-08 |
| CN104902754A (zh) | 2015-09-09 |
| HK1214552A1 (zh) | 2016-07-29 |
| EP2914112A1 (en) | 2015-09-09 |
| PH12015501002A1 (en) | 2015-07-27 |
| US20150297579A1 (en) | 2015-10-22 |
| EP2914112A4 (en) | 2016-06-15 |
| NI201500063A (es) | 2015-09-10 |
| MX2015005548A (es) | 2016-01-15 |
| AU2013337352A1 (en) | 2015-05-21 |
| JP2015535291A (ja) | 2015-12-10 |
| IL238563A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
| IN2015DN00450A (enExample) | ||
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EA201491391A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| PL3725810T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego | |
| EA201591754A1 (ru) | Человеческие антитела к na1.7 | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| MX2021000538A (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| PH12014502449A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
| PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| JP2015535291A5 (enExample) | ||
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| EA201990403A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders |